Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00916 ...
Drug Name Metronidazole
Molecular Weight 171.154
Molecular Formula C6H9N3O3
CAS Number 443-48-1
SMILES CC1=NC=C(N1CCO)[N+]([O-])=O
External Links
DRUGBANK DB00916
T3DB T3D4703
PubChem Compound 4173
PDR 1047
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P -0.02 - -0.02 - http://www.t3db.ca/toxins/T3D4703
Boiling Point 405.4 ℃ 405.4 ℃ http://www.emelcabio.com/metronidazole-41310008.html
Melting Point 160.0 ℃ 160 ℃ http://www.inchem.org/documents/pims/pharm/metronid.htm
pKa 2.57 - 2.57,15.42 - http://www.t3db.ca/toxins/T3D4703
pKa 15.42 - 2.57,15.42 - DRUGBANK
Log S -1.5 - -1.5 - http://www.t3db.ca/toxins/T3D4703

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 122000.0 ng.h/ml 122±10.3 mg.h/l Oral single dose; DRUGBANK
Bioavailability 90.0 % >90 % Tablet, PO, oral; DRUGBANK
Bioavailability 99.0 % 99±8 % PO, oral; The Pharmacological Basis of Therapeutics
Bioavailability 74.5 % 67-82 % Rectal Administration; The Pharmacological Basis of Therapeutics
Bioavailability 53.0 % 53±16 % Vaginal Administration; The Pharmacological Basis of Therapeutics
C Max 35000.0 ng/ml 30-40 mg/L intravenous infusion, IV in drop; DRUGBANK
C Max 26000.0 ng/ml 26.0 mg/L DRUGBANK
C Max 10500.0 ng/ml 8-13 mg/L Oral single dose; DRUGBANK
C Max 19800.0 ng/ml 19.8 mcg/ml The Pharmacological Basis of Therapeutics
C Max 1900.0 ng/ml 1.9±0.2 mcg/ml Vaginal Administration; The Pharmacological Basis of Therapeutics
C Max 27000.0 ng/ml 27(11-41) mcg/ml intravenous infusion, IV in drop; The Pharmacological Basis of Therapeutics
T Max 1.0 h 1 h intravenous infusion, IV in drop; DRUGBANK
T Max 2.1 h 0.25-4 h Oral single dose; DRUGBANK
T Max 2.8 h 2.8 h The Pharmacological Basis of Therapeutics
T Max 11.0 h 11±2 h Vaginal Administration; The Pharmacological Basis of Therapeutics
Tss 72.0 h 3 day DRUGBANK
Clearance 0.35 L/h/m2 10.0 ml/min/1.73m2 Renal clearance; DRUGBANK
Clearance 4.3 L/h/kg 2.1-6.4 L/h/kg Total clearance; DRUGBANK
Clearance 0.0780 L/h/kg 1.3±0.3 ml/min/kg Neonates ↓ ;Elderly → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;Crohn → ; The Pharmacological Basis of Therapeutics
Clearance 0.0510 L/h/kg 0.85 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.80 L/kg 0.51-1.1 L/kg Steady state volume of distribution; adults; DRUGBANK
Volume of Distribution 0.74 L/kg 0.74±0.10 L/kg Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;Crohn → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.40 L/kg 0.4 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 7.3 h 7.3±1.0 h elimination half-life; normal,healthy; DRUGBANK
Half-life 8.0 h 6-10 h elimination half-life; different study; DRUGBANK
Half-life 8.5 h 8.5±2.9 h Neonates ↑ ;Preg, pregnant → ;Children → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Crohn → ; The Pharmacological Basis of Therapeutics
Half-life 7.1 h 7.1 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 5000.0 mg/kg 5000.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 20.8 mg/kg/h 500.0 mg/kg/day PO, oral; Rattus, Rat; T3DB
Eliminate Route 70.0 % 60-80 % Urinary excretion; DRUGBANK
Eliminate Route 10.5 % 6-15 % Faeces excretion; DRUGBANK
Eliminate Route 10.0 % 10±2 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 20.0 % <20 % plasma proteins; DRUGBANK
Protein Binding 11.0 % 11±3 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for neonates 30.0 mg/kg/day 30 mg/kg/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for neonates 22.5 mg/kg/day 22.5 mg/kg/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for neonates 15.0 mg/kg/day 15 mg/kg/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for infants 50.0 mg/kg/day 50 mg/kg/day PO, oral Flagyl Capsules metronidazole PDR
Max dose for infants 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for children 50.0 mg/kg/day 50 mg/kg/day PO, oral Flagyl Capsules metronidazole PDR
Max dose for children 2250.0 mg/kg/day 2250 mg/kg/day PO, oral Flagyl Capsules metronidazole PDR
Max dose for children 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for children 4000.0 mg/day 4 g/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for adolescents 50.0 mg/kg/day 50 mg/kg/day PO, oral Flagyl Capsules metronidazole PDR
Max dose for adolescents 2250.0 mg/kg/day 2250 mg/kg/day PO, oral Flagyl Capsules metronidazole PDR
Max dose for adolescents 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for adolescents 4000.0 mg/day 4 g/day intravenous injection, IV Flagyl Capsules metronidazole PDR
Max dose for adults 4000.0 mg/day 4 g/day PO, oral;intravenous injection, IV; Flagyl Capsules metronidazole PDR
Max dose for geriatric 4000.0 mg/day 4 g/day PO, oral;intravenous injection, IV; Flagyl Capsules metronidazole PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1